Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis)

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 2020-2028

  Kager, L M ^a,b,c   Wiersinga, W J ^a,b,c   Roelofs, J J T H ^d   Meijers, J C M ^d   Levi, M ^c   Van'T Veer, C ^a,b   Van der Poll, T ^a,b,c  

^a Center for Infection and Immunity Amsterdam CINIMA   (Netherlands)

^b Center for Experimental and Molecular Medicine   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Department of Pathology ^*  (Netherlands)

Author keywords

Coagulation; Fibrinolysis; Inflammation; Melioidosis; Plasminogen activator inhibitor type 1 (PAI 1); Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN; ASPARTATE AMINOTRANSFERASE; CYTOKINE; D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL LOAD; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNITY; INFECTION RISK; LIVER CELL DAMAGE; MALE; MELIOIDOSIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; BURKHOLDERIA PSEUDOMALLEI; MALE; MELIOIDOSIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEPSIS;

EID: 80053428231     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04473.x     Document Type: Article

References (39)

1. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4: 272-82.
2. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18: 383-416.
3. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20-year Darwin prospective study. PLoS Negl Trop Dis 2010; 4: e900.
4. Choi G, Schultz MJ, van Till JW, Bresser P, van der Zee JS, Boermeester MA, Levi M, van der Poll T. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24: 786-9.
5. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
6. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood 2009; 114: 2367-74.
7. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
8. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26-34.
9. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
10. Marshall LJ, Ramdin LS, Brooks T, DPhil PC, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003; 171: 2057-65.
11. Arndt PG, Young SK, Worthen GS. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway. J Immunol 2005; 175: 4049-59.
12. Song Y, Lynch SV, Flanagan J, Zhuo H, Tom W, Dotson RH, Baek MS, Rubio-Mills A, Singh G, Kipnis E, Glidden D, Brown R, Garcia O, Wiener-Kronish JP. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 2007; 106: 252-61.
13. Rijneveld AW, Florquin S, Bresser P, Levi M, de Waard V, Lijnen R, van der Zee JS, Speelman P, Carmeliet P, van der Poll T. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102: 934-9.
14. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-5.
15. Iba T, Kidokoro A, Fukunaga M, Sugiyama K, Sawada T, Kato H. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005; 23: 25-9.
16. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
17. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EK. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-62.
18. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-8.
19. Renckens R, Roelofs JJ, Bonta PI, Florquin S, de Vries CJ, Levi M, Carmeliet P, van't Veer C, van der Poll T. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007; 109: 1593-601.
20. Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, Xu H, Andalibi A, Feng XH, Zhu H, Huang Y, Zhang W, Weng X, Yan C, Yin Z, Briles DE, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007; 27: 349-60.
21. Wiersinga WJ, Meijers JC, Levi M, van't Veer C, Day NP, Peacock SJ, van der Poll T. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008; 6: 32-9.
22. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, Limmathurotsakul D, Chierakul W, Leendertse M, Florquin S, de Vos AF, White N, Dondorp AM, Day NP, Peacock SJ, van der Poll T. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Med 2007; 4: e248.
23. Wiersinga WJ, de Vos AF, Wieland CW, Leendertse M, Roelofs JJ, van der Poll T. CD14 impairs host defense against gram-negative sepsis caused by Burkholderia pseudomallei in mice. J Infect Dis 2008; 198: 1388-97.
24. Verheijen JH, Mullaart E, Chang GT, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-9.
25. Wiersinga WJ, Kager LM, Hovius JW, van der Windt GJ, de Vos AF, Meijers JC, Roelofs JJ, Dondorp A, Levi M, Day NP, Peacock SJ, van der Poll T. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 2010; 184: 3079-86.
26. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-11.
27. Weijer S, Wieland CW, Florquin S, van der Poll T. A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis. Blood 2005; 106: 2761-8.
28. Strieter RM, Belperio JA, Keane MP. Cytokines in innate host defense in the lung. J Clin Invest 2002; 109: 699-705.
29. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
30. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009; 113: 1358-64.
31. Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 1992; 258: 1004-7.
32. Schouten M, van't Veer C, van den Boogaard FE, Gerlitz B, Grinnell BW, Roelofs JJ, Levi M, van der Poll T. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010; 202: 1600-7.
33. Lauw FN, Simpson AJ, Prins JM, Smith MD, Kurimoto M, van Deventer SJ, Speelman P, Chaowagul W, White NJ, van der Poll T. Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J Infect Dis 1999; 180: 1878-85.
34. Simpson AJ, Smith MD, Weverling GJ, Suputtamongkol Y, Angus BJ, Chaowagul W, White NJ, van Deventer SJ, Prins JM. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis 2000; 181: 621-5.
35. Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun 1999; 67: 3593-600.
36. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999; 107: 54-61.
37. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25: 450-5.
38. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000; 165: 1513-19.
39. Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen HR, Carmeliet P, van der Poll T. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 2005; 3: 1018-25.